Evidence map›Paper›PMID 36159788›Full record

ArticleFrontiers in immunology2022

The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism.

Qi Wang, Yang Wang, Wenying Qiao, Bin Xu, Yanmin Liu, Xiaodan Zhang, Wenjuan Li, Juan Zhao, Mengcheng Liu, Yang Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. The treatment of primary biliary cholangitis: from shadow to light.Therapeutic advances in gastroenterology · 2024
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qi WangBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Yang WangBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Wenying QiaoBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Bin XuSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Yanmin LiuSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Xiaodan ZhangSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Wenjuan LiSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Juan ZhaoSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Mengcheng LiuBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Yang ZhangBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Dexi ChenBeijing Institute of Hepatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Chunyang HuangSecond Department of Liver Disease Center, Beijing You 'an Hospital, Capital Medical University, Beijing, China.
Ronghua JinNational Center For Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In primary biliary cholangitis (PBC), the levels of serum IL-2 were involved in liver inflammation and immune changes. This study aimed to investigate the prognostic significance of serum IL-2 combined with total bilirubin (TBIL) in liver failure and cytokine changes during the disease. Methods: A total of 160 PBC patients treated with UDCA were included. Parameters at admission were collected, and the COX regression model was used to predict independent risk factors associated with PBC disease progression. We identified the optimal cut-off values and prognosis effects of serum IL-2 and TBIL based on the time-dependent receiver operating characteristic (ROC) curve. We also analyzed the incidence of liver failure with Kaplan-Meier survival analysis. In addition, the changes of cytokines (mainly IL-2) in liver tissues and blood samples from 11 patients with end-stage PBC liver failure and five healthy controls were examined. Results: Age, IL-2, ALB, γ-GT, ALP, TBIL, Hb, TBA, WBC, and PLT, as well as anti-Sp100, were found to be independent risk factors in PBC patients with liver failure. Patients with decreased serum IL-2 levels and increased TBIL levels have a significantly higher incidence of liver failure and a worse prognosis. Patients with advanced PBC liver failure after liver transplantation exhibited a significant decrease in levels of serum IL-2 and a relatively immunosuppressed status. Conclusions: The combination of serum IL-2 and TBIL can be a predictor of the progression of liver failure in patients with primary biliary cholangitis, and it is likely to be related to the expression of GM-CSF and G-CSF.

Indexed as

Liver Cirrhosis, BiliaryLiver FailureBilirubinGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHumansInterleukin-2PrognosisBilirubinGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorIL2 protein, humanInterleukin-2IL-2immuneliver failureprimary biliary cholangitisprognosis

Identifiers

PMID36159788
PMCPMC9493093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.